G&A at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s G&A?
- Immix Biopharma, Inc. (IMMX) reported G&A of $4.82M in Q1 2026.
- How has Immix Biopharma, Inc.'s G&A changed year-over-year?
- Immix Biopharma, Inc.'s G&A increased by 78.1% year-over-year, from $2.71M to $4.82M.
- What is the long-term trend for Immix Biopharma, Inc.'s G&A?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s G&A has grown at a 82.8% compound annual growth rate (CAGR), from $1.23M to $13.7M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.